Patient preferences for attributes of tyrosine kinase inhibitor treatments for EGFR mutation-positive non-small-cell lung cancer

John Fp Bridges; Marie de la Cruz; Melissa Pavilack; Emuella Flood; Ellen M Janssen; Nabil Chehab; Ancilla W Fernandes

doi:10.2217/fon-2019-0396

Patient preferences for attributes of tyrosine kinase inhibitor treatments for EGFR mutation-positive non-small-cell lung cancer

Future Oncol. 2019 Dec;15(34):3895-3907. doi: 10.2217/fon-2019-0396. Epub 2019 Oct 17.

Authors

John Fp Bridges¹, Marie de la Cruz², Melissa Pavilack³, Emuella Flood^{2

3}, Ellen M Janssen², Nabil Chehab³, Ancilla W Fernandes³

Affiliations

¹ Department of Biomedical Informatics, The Ohio State University College of Medicine, Columbus, OH 43210, USA.
² Patient Centered Outcomes, ICON, Gaithersburg, MD 20807, USA.
³ AstraZeneca, Gaithersburg, MD 20807, USA.

PMID: 31621403
DOI: 10.2217/fon-2019-0396

Abstract

Aim: EGFR-tyrosine kinase inhibitors (TKIs) vary in efficacy, side effects (SEs) and dosing regimen. We explored EGFR-TKI treatment attribute preferences in EGFR mutation-positive metastatic non-small-cell lung cancer. Materials & methods: Patients completed a survey utilizing preference elicitation methods: direct elicitation of four EGFR-TKI profiles describing progression-free survival (PFS), severe SE risk, administration; discrete choice experiment involving 12 choice tasks. Results: 90 participated. The preferred profile (selected 89% of times) had the longest PFS (18 months) and the lowest severe SE risk (5%). Patients would need compensation with ≥three-times longer PFS for severe SEs. Patients would accept ≤7 months PFS reduction for oral treatments versus intravenous. Conclusion: Patients preferred longer PFS but were willing to accept reduced PFS for more favorable SEs and dosing convenience.

Keywords: DCE; EGFR; EGFR-TKIs; NSCLC; direct elicitation; patient preferences; treatment attributes.

Publication types

Observational Study

MeSH terms

Administration, Oral
Aged
Aged, 80 and over
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / genetics
Carcinoma, Non-Small-Cell Lung / mortality
Diarrhea / chemically induced
Diarrhea / diagnosis
Diarrhea / psychology
ErbB Receptors / antagonists & inhibitors
ErbB Receptors / genetics
Fatigue / chemically induced
Fatigue / diagnosis
Fatigue / psychology
Female
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / genetics
Lung Neoplasms / mortality
Male
Middle Aged
Mutation
Nausea / chemically induced
Nausea / diagnosis
Nausea / psychology
Patient Preference / psychology*
Patient Preference / statistics & numerical data
Progression-Free Survival
Protein Kinase Inhibitors / administration & dosage*
Protein Kinase Inhibitors / adverse effects
Retrospective Studies
Severity of Illness Index
Surveys and Questionnaires / statistics & numerical data
Time Factors
Vomiting / chemically induced
Vomiting / diagnosis
Vomiting / psychology

Substances

Protein Kinase Inhibitors
EGFR protein, human
ErbB Receptors